A decision on whether Britain’s National Health Service will cover the drug is expected in November.
However, with the arrival of the first GLP-1 pill Wegovy (semaglutide) from Danish competitor Novo Nordisk which launched in the U.S. and U.K. this year and is soon expected in some EU countries dem… [+853 chars]
Discussion (0)
No comments yet. Be the first to share your thoughts!
Join the Conversation
You need to be logged in to leave a comment.
Sign In Create Account